Clinical Trial Update: Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP [Phase 2]

View source ↗

Summary

Completion of a Phase 2 clinical trial evaluating the anti-tumor activity and tolerability of the PARP inhibitor 2X-121 in patients with metastatic breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 2X-121

Snippet

Sponsor: Allarity Therapeutics | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED